-+ 0.00%
-+ 0.00%
-+ 0.00%

GENENTECH ANNOUNCES POSITIVE PHASE II RESULTS FOR DUAL GLP-1/GIP RECEPTOR AGONIST ENICEPATIDE IN PEOPLE LIVING WITH TYPE 2 DIABETES AND OVERWEIGHT OR OBESITY

Reuters·09/22/2026 05:05:00

Please log in to view news